Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
Evgen Pharma
company
About
Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions
- 1 - 10
Details
- Last Funding Type
- Series A
- Industries
- Biotechnology,Medical,Pharmaceutical
- Founded date
- Jan 1, 2007
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
£460K
Evgen Pharma has raised a total of
£460K
in funding over 2 rounds. Their latest funding was raised on
Jul 25, 2012 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 25, 2012 | Series Unknown | £460K | 1 | — | — | Detail |
| Sep 20, 2011 | Series A | — | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Evgen Pharma is funded by 2 investors.
Sarum Partners
and Rising Stars Growth Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Sarum Partners
|
— | Series Unknown |
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
